Delirium cordis: can we predict the onset of atrial fibrillation?

The Lancet

Volumn 373, Issue 9665, 2009, Pages 698-700

  Brieger, David B ^a   Freedman, S Ben ^a,b  

^a UNIVERSITY OF SYDNEY   (Australia)

^b Department of Microbiology and Infectious Diseases   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIARRHYTHMIC AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DRONEDARONE; FISH OIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

AGING; ARTICLE; CARDIOVASCULAR RISK; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; ECHOCARDIOGRAPHY; HEART ATRIUM FIBRILLATION; HUMAN; INCIDENCE; PREVALENCE; PRIMARY PREVENTION; PRIORITY JOURNAL; PROPHYLAXIS; SECONDARY PREVENTION;

EID: 60649115084     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(09)60415-3     Document Type: Note

References (14)

1. Miyasaka Y., Barnes M.E., Gersh B.J., et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation 114 (2006) 119-125
2. Furberg C.D., Psaty B.M., Manolio T.A., Gardin J.M., Smith V.E., and Rautaharju P.M. Prevalence of atrial fibrillation in elderly subjects (the Cardiovascular Health Study). Am J Cardiol 74 (1994) 236-241
3. WHO. Neurological disorders: public health challenges (2006). www.who.int/entity/mental_health/neurology/neurological_disorders_report_web.pdf (accessed Nov 27, 2008).
4. Wyse D.G., Waldo A.L., DiMarco J.P., et al., on behalf of the AFFIRM writing group. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 347 (2002) 1825-1833
5. Roy D., Talajic M., Nattel S., et al., on behalf of the Atrial Fibrillation and Congestive Heart Failure Investigators. Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med 358 (2008) 2667-2677
6. Hohnloser S.H., Connolly S.J., Crijns H.J.G.M., Page R.L., Seiz W., and Torp-Petersen C. Rationale and design of ATHENA: a placebo-controlled, double-blind, parallel arm trial to assess the efficacy of dronedarone 400 mg bid for the prevention of cardiovascular hospitalization or death from any cause in patients with atrial fibrillation/atrial flutter. J Cardiovasc Electrophysiol 19 (2008) 69-73
7. Fauchier L., Pierre B., de Labriolle A., Grimard C., Zannad N., and Babuty D. Antiarrhythmic effect of statin therapy and atrial fibrillation: a meta-analysis of randomized controlled trials. J Am Coll Cardiol 51 (2008) 828-835
8. Healey J.S., Baranchuk A., Crystal E., et al. Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis. J Am Coll Cardiol 45 (2005) 1832-1839
9. Mayson S.E., Greenspon A.J., Adams S., et al. The changing face of postoperative atrial fibrillation prevention: a review of current medical therapy. Cardiol Rev 15 (2007) 231-241
10. Calo L., Bianconi L., Colivicchi F., et al. N-3 Fatty acids for the prevention of atrial fibrillation after coronary artery bypass surgery: a randomized, controlled trial. J Am Coll Cardiol 45 (2005) 1723-1728
11. Schnabel R.B., Sullivan L.M., Levy D., et al. Development of a risk score for atrial fibrillation (Framingham Heart Study): a community-based cohort study. Lancet 373 (2009) 739-745
12. Gage B.F., Waterman A.D., Shannon W., Boechler M., Rich M.W., and Radford M.J. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 285 (2001) 2864-2870
13. Karjalainen J., Kujala U.M., Kaprio J., Sarna S., and Viitasalo M. Lone atrial fibrillation in vigorously exercising middle aged men: case-control study. BMJ 316 (1998) 1784-1785
14. Gami A.S., Hodge D.O., Herges R.M., et al. Obstructive sleep apnea, obesity, and the risk of incident atrial fibrillation. J Am Coll Cardiol 49 (2007) 565-571